

# Anti-PD-L1 (Extracellular region) M051 Antibody

Catalog # AN1896

## Product Information

---

<b>Application</b>	WB, ICC, IP
<b>Primary Accession</b>	<a href="#">Q9NZQ7</a>
<b>Host</b>	Mouse
<b>Clonality</b>	Mouse Monoclonal
<b>Isotype</b>	IgG1
<b>Clone Names</b>	M051
<b>Calculated MW</b>	33275

## Additional Information

---

<b>Gene ID</b>	29126
<b>Other Names</b>	Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1
<b>Dilution</b>	WB~~1:1000 ICC~~N/A IP~~N/A
<b>Storage</b>	Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
<b>Precautions</b>	Anti-PD-L1 (Extracellular region) M051 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
<b>Shipping</b>	Blue Ice

## Background


---

Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The B7 family members have conserved regions that include extracellular IgV and IgC domains, and a short cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas. PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, which promotes tumor survival. The blockage of the PD1/PD-L1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. Several therapies that target PD1/PD-L1 pathways are currently in use or in clinical trials


## Images

---


Western blot of human recombinant PD-L1 extracellular



region (40 kDa; lanes 1 & 3) and endogenous PD-L1 in human lung (lanes 2 & 4). The blot was probed with mouse monoclonals anti-PD-L1 (AN1896) at 1:500 (lanes 1 & 2) and anti-PD-L1 (PM0801) at 1:250 (lanes 3 & 4).



Immunocytochemical labeling of PD-L1 in aldehyde fixed human MDA-MB-231 carcinoma cells untreated (A) or treated with 100 ng/ml IFN $\gamma$  for 48 hrs (B). The cells were labeled with mouse monoclonal anti-PD-L1 (AN1896). The antibody was detected using goat anti-mouse DyLight® 594.



Representative Standard Curve using mouse monoclonal anti-PD-L1 (AN1896) for ELISA capture of human recombinant PD-L1 extracellular region with a His-tag. Captured protein was detected by suitable anti-His-tag antibody followed by appropriate secondary antibody HRP conjugate.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.